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Short report Circulating lymphocyte number has a positive 
association with tumor response in neoadjuvant 
chemoradiotherapy for advanced rectal cancer
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Abstract
Although neoadjuvant chemoradiotherapy (CRT) is the standard treatment for advanced rectal cancer (RC), markers to 
predict the treatment response have not been fully established. In 73 patients with advanced RC who underwent CRT 
in a neoadjuvant setting, we retrospectively examined the associations between the clinical effects of CRT and blood 
cell counts before and after CRT. Clinical or pathological complete response (CR) was observed in 10 (14%) cases. The 
CR rate correlated significantly with the size and the circumferential extent of the tumor. Hemoglobin level, white 
blood cell (WBC) count and platelet count before CRT did not show a significant difference between CR and non-CR 
cases. Interestingly, however, lymphocyte ratio in WBC was significantly higher (p = 0.020), while neutrophil ratio 
tended to be lower (p = 0.099), in CR cases, which was shown to be an independent association by multivariate 
analysis. When all the blood data obtained in the entire treatment period were evaluated, circulating lymphocyte 
count was most markedly decreased in the CRT period and gradually recovered by the time of surgery, while the 
numbers of neutrophils and monocytes were comparatively stable. Moreover, the lymphocyte percentage in samples 
obtained from CR patients was maintained at a relatively higher level than that from non-CR patients. Since tumor 
shrinkage is known to be dependent not only on the characteristics of tumor cells but also on various host conditions, 
our data raise the possibility that a lymphocyte-mediated immune reaction may have a positive role in achieving 
complete eradication of tumor cells. Maintenance of circulating lymphocyte number may improve the response to CRT 
in rectal cancer.
Findings
Preoperative chemoradiotherapy (CRT) is currently used
worldwide as the initial treatment for advanced RC, since
it can produce down-staging in approximately half of
patients with locally advanced rectal cancer RC, resulting
in a lower rate of postoperative local recurrence and a
higher rate of sphincter-preserving surgery as well as lon-
ger survival [1-3]. However, in unresponsive cases, it may
have disadvantages such as delaying surgery or immune
suppression. Although many clinical factors [4,5], radio-
logic findings [6,7] and molecular markers [7-10] have
been suggested to be related to the therapeutic response,
the clinical usefulness of these markers remains contro-
versial, and thus, identifying factors that can predict the
efficacy of neoadjuvant CRT is essential for decision-
making in the management of patients with RC.
In this study, we retrospectively examined circulating
blood cells before and after CRT and assessed the possi-
ble relationship between these laboratory values and
tumor response to CRT, with the approval of the Ethics
Committee of the University of Tokyo. Seventy-three
patients with rectal adenocarcinoma newly diagnosed
between November 2004 and August 2009 received CRT
at Tokyo University Hospital. All the patients received a
total dose of 50.4Gy radiation and concomitant 5-FU-
based chemotherapy. Peripheral blood data were investi-
gated from the medical records of these patients. Pre-
CRT blood data were obtained from samples collected 0-
53 days before the start of CRT, and all the blood data
during the period from the start of CRT to surgery were
also examined in each patient. Of the 73 patients, 69
underwent total mesorectal excision in the Department
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o f  S u r g i c a l  O n c o l o g y .  I n  7  c a s e s ,  n o  t u m o r  c e l l s  w e r e
detected at either the primary site or in regional lymph
nodes on pathological examination, confirming patholog-
ical complete response (pCR). Three other patients
showed a clinical CR (cCR) after CRT, with no detectable
cancer cells on multiple biopsy specimens, and were thus
followed without surgery and showed no evidence of
recurrence for more than 12 months, and were also
included in the CR group. The clinical and pathological
data of the 10 CR and other 63 non-CR cases are shown
in Table 1. Patients with tumors with circumferential size
more than 4.0 cm determined by computed tomography
(CT) showed a significantly lower CR rate than those
with tumors less than 4.0 cm (p < 0.05). Also, tumors with
a circumferential extent of more than 60% determined by
colonoscopy were relatively resistant (p < 0.05). However,
none of the other factors, including chemotherapeutic
regimen, was significantly associated with the CR rate.
In the 73 patients, blood data on hemoglobin (Hb),
white blood cells (WBC) with their subpopulations, and
platelets were examined at various time points before
CRT and during and after CRT until surgery. First, we
evaluated blood cell data before CRT in 10 CR and 63
non-CR cases. None of Hb, WBC and platelet counts
showed any significant difference between CR and non-
CR cases. Interestingly, however, the numbers of lympho-
cytes and neutrophils showed different associations with
tumor response. As shown in Figure 1, CR cases showed a
relatively lower neutrophil count, while lymphocyte
count tended to be higher in CR cases. If the percentage
of lymphocytes in the total WBC population was com-
pared, CR cases had a significantly higher percentage of
lymphocytes than that in non-CR cases (p = 0.020). With
multivariate stepwise logistic regression analysis, the pre-
CRT lymphocyte percentage, but not tumor size, showed
an independent correlation with CR rate (Table 2).
However, the blood cell counts appeared to change dur-
ing the treatment period. Therefore, we next examined
the numbers of leukocyte subpopulations, i.e., neutro-
phils, monocytes and lymphocytes, in all the blood sam-
ples taken from these patients from the start of CRT to
surgery (or to the first biopsy in 3 CR patients who did
not undergo surgery). As shown in Figure 2, the numbers
of circulating neutrophils and monocytes were relatively
stable during the treatment period. In contrast, the num-
ber of circulating lymphocytes was markedly reduced
during CRT and showed a gradual increase up to the time
of surgery. When the lymphocyte count in the total blood
samples was compared between CR and non-CR cases,
samples derived from the CR group tended to contain
more lymphocytes than those from the non-CR group
(Figure 3). In contrast, neutrophil percentage was higher
in non-CR cases (data not shown). Because this was a ret-
rospective study and the timing and frequency of blood
tests varied markedly among patients, the comparison
may not be significant from the statistical point of view,
and a prospective study is necessary to draw a firm con-
clusion on this point. However, our data raise the possi-
bility that circulating lymphocytes may have significant
biological effects on the tumor response to CRT.
Peripheral lymphopenia, especially reduced T lympho-
cytes, after RT was first described in the 1970's [11,12],
but the clinical significance of this drop in the circulating
lymphocyte count has not been well evaluated. A litera-
ture search yielded no previous report of a significant
correlation between circulating lymphocyte count and
RT response. However, the degree of recovery of lympho-
cyte count after RT has been shown to correlate with
tumor recurrence [13,14]. These facts allow us to specu-
late that the radiation-induced depression of circulating
lymphocyte may provide an opportunity for re-growth
via proliferation of tumor cells that survived the irradia-
tion damage, thereby reducing the likelihood of CR after
RT.
In fact, radiosensitivity has been shown to be depen-
dent not only on the biological characteristics of tumor
cells but also on the tumor microenvironment [15,16].
Although circulating leukocyte count reflects the host
immune status, neutrophils usually act as the first
responders to microbial infection in acute inflammation,
while lymphocytes recognize specific "non-self" antigens
and eliminate a specific pathogen or pathogen-infected
cells. Since tumor cells usually have a tumor-associated
antigen, lymphocytes, especially T cells, are thought to
play a central role in anti-tumor immunity, and the abso-
lute number of host lymphocytes could be biologically
relevant for tumor response to CRT. Since the first report
in 1979, [17], it has been proposed that tumor shrinkage
is not simply dependent on direct damage to irradiated
tumor cells, but also to be greatly affected by the host
immune response [18]. In fact, in vivo studies have sug-
gested that cancer cells, dead or dying due to radiother-
apy or chemotherapy, can present tumor-associated
antigens to host immune cells and thereby evoke anti-
tumor immune responses [19,20]. Moreover, accumulat-
ing clinical data suggest the presence of radiation-
induced anti-tumor immunity in humans [21,22]. There-
fore, the marked reduction in the circulating lymphocyte
count during CRT may be a significant disadvantage for
patients. Together with these facts, our observations sug-
gest the possibility that the lymphocyte-mediated
immune response against damaged tumor cells is impor-
tant for achieving CR during CRT in RC cases.
In our data, the association between lymphocyte ratio
and clinical efficacy was observed in primary tumor, but
not in metastatic lymph nodes (data not shown). Since
tumor shrinkage is more dependent on local immune
response, this may be reasonable that the clinical effectsKitayama et al. Radiation Oncology 2010, 5:47
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Table 1: Correlation between clinical and pathological factors before CRT and pathologica Response in rectal cancer 
patientsl
Non-CR (63) CR (10) p value
Age (years) 63.4 ± 9.9 65.4 ± 11.2 0.455
Sex
Male 39 6 0.908
Female 24 4
T stage
2 12 1 0.901
34 5 8
46 1
N stage
0 49 9 0.487
11 4 1
Clinical stage
≤2 48 9 0.327
≥3 15 1
Histology
Differentiated 61 9 0.313
Undifferentiated 2 1
Size
≤40 mm 29 8 0.046*
>40 mm 34 2
Circumferential extent
≤60% 27 8 0.029*
>60% 36 2
Distance from anal verge
>5 cm 21 5 0.307
≤5 cm 42 5
Chemo regimen
UFT+LV 55 6 0.148
5Fu 4 2
S1 4 2
CEA
>5.0 ng/ml 35 3 0.120
≤5.0 ng/ml 27 7
The size of the tumor was defined as the largest diameter determined by CT, and circumferential extent and distance from the anal verge were 
determined by colonoscopy
performed before CRT
*: p < 0.05Kitayama et al. Radiation Oncology 2010, 5:47
http://www.ro-journal.com/content/5/1/47
Page 4 of 6
during CRT are largely different between in lymph nodes
and in primary tumors. Further analysis on tumor infil-
trating lymphocytes (TIL) in malignant tissues is essential
to see the accurate contribution of host immune reaction
on CRT response.
I n  c o n t r a s t  t o  l y m p h o c y t e s ,  t h e  n e u t r o p h i l  c o u n t
showed an inverse correlation with tumor response. An
increase in neutrophil count usually reflects an acute
inflammatory response against bacterial infection. In our
series, other inflammatory markers, such as platelet
count and serum levels of C reactive protein (CRP) and
fibrinogen also showed a similar association, although
not statistically significant (data not shown). Previous
studies have shown that neutrophils can suppress the T
Table 2: Multivariate analysis of Complete response (CR) rate
Variable Odds (95% CI) p value
Circumferential extent (>60% vs. ≤60%) 3.833 0.115
Platelet count 1.063 (0.983-1.178) 0.141
% Lymphocytes in WBC 0.676 (0.415-0.947) 0.019
% Neutrophils in WBC 0.735 (0.478-1.004) 0.054
The independence of five factors with a possible correlation with CR rate were analyzed by stepwise logistic regression analysis using JMP 
software 8.0.
Figure 1 Hemoglobin (Hb), white blood cell (WBC) and platelet counts (A) as well as white blood cell subpopulations (B) in circulating blood 
taken before CRT in 10 CR and 63 non-CR cases. *: p < 0.05 by paired t-test.
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cell response through the production of reactive oxygen
species (ROS), nitric oxide (NO) and arginase [23,24].
This suggests that the presence of an acute inflammatory
response during CRT may cause suppression of lympho-
cyte-mediated immunity through increased circulating
neutrophils and thus elicit unfavorable effects on tumor
response.
Although the results obtained from this retrospective
analysis have limitations, the significant association
between the circulating lymphocyte number and CR rate
supports the hypothesis that total eradication of tumor
c e l l s  a f t e r  CR T  i s  d e pe n d e n t,  a t  l e a s t  i n  p a rt,  o n  h o s t
immune reaction. Enhancing lymphocyte-mediated
immunity during CRT may be a lead to the improvement
of the clinical efficacy of CRT in RC patients. Further
analysis of the phenotypic and functional characteristics
of circulating as well as tumor infiltrating lymphocytes
may clarify the novel mechanisms underlying the respon-
siveness of tumors to CRT.
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Figure 2 Change in ratio of neutrophils (A), monocytes (B) and lymphocytes (C) in peripheral blood samples during entire preoperative 
treatment period. Each dot shows the values obtained from all the patients during this period. As compared with neutrophils and monocytes, 
the lymphocyte percentage was markedly reduced during CRT and gradually recovered over several weeks after the end of CRT until surgery.
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Figure 3 Ratio of lymphocytes in WBC tended to be maintained at 
a relatively higher level in 10 CR cases as compared with 63 non-
CR cases. When all the blood data were grossly compared, statistical 
significance was obtained. *: p < 0.001 by ANOVA.
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